Drug manufacturers are facing potentially high-dollar claims in class actions for “medical monitoring.” Although this claim evolved in cases involving environmental exposure to toxic chemicals, the theory has migrated to prescription drugs, leaving both companies and courts to struggle with the resulting doctrinal and policy issues.

Traditionally, product liability claims over drug sales involve plaintiffs alleging current injury from the product. The necessary emphasis on family medical history, pre-existing conditions, individual lifestyles and variations among patients in the warnings seen, heard or relied upon often preclude class certification.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]